I5NP for Prophylaxis of Delayed Graft Function in Kidney Transplantation

Completed · Phase 1/Phase 2

Conditions studied: Delayed Graft Function, Other Complication of Kidney Transplant

In brief

The purpose of this study is to determine whether a single administration of QPI-1002 (also known as I5NP) can prevent DGF in patients undergoing deceased donor kidney transplantation. In this Phase I /II study, patients who are undergoing renal transplantation with organs from DCD donors, ECD donors or SCD donors with ≥ 24 hours of cold ischemia time who meet study entry criteria will be studied to evaluate the safety and pharmacokinetic profile of I5NP (Part A) and clinical activity of I5NP administration (Part B). Data from this study will be used to identify doses of I5NP to be used in follow-on efficacy studies. Part A will be a randomized, dose escalation study to determine the highest or maximum tolerated dose (MTD). Part A will enroll 40 patients at approximately 20 sites; patients will be randomized to receive either I5NP or placebo in a ratio of 8:2 in each cohort (cohorts 1-4). Part B will utilize the dose identified in Part A to further evaluate, in a double-blind manner, the safety, and clinical activity of I5NP. In Part B, up to 326 patients will participate at approximately 60 sites; up to 163 patients will be randomized to receive I5NP and up to 163 patients randomized to receive placebo.

Key facts

Study ID

NCT00802347

Run by

Quark Pharmaceuticals

People needed

374

Starts

2008-12-01

Expected to finish

2014-05-01

Last updated by the study team

2014-09-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient is at least 18 years of age.
• Patient has given informed consent.
• Patient is willing to practice birth control. Female patients must be: (1) post-menopausal (2) surgically sterile, or (3) using an effective means of contraception (per the site-specific guidelines or using 2 methods of birth control concurrently, whichever is more stringent) which will be continued until the Study Day 90 visit with a negative pregnancy test within 48 hours prior to administration of study drug. Male patients with female partners of child bearing potential must agree to use an effective means of contraception (per the site-specific guidelines or using 2 methods of birth control concurrently, whichever is more stringent) which will be continued until the Study Day 90 visit. Note: For the purpose of this study, post menopausal is defined as the absence of menses consistent with ESRD. A woman is considered to be surgically sterilized if she has had a bilateral tubal ligation for at least 6 months prior to administration of study drug, bilateral oophorectomy, or complete hysterectomy.
• Women of childbearing potential test negative for pregnancy (either urine or serum) within 48 hours prior to transplant.
• Patient is up-to-date on cancer screening according to site-specific guidelines and the past medical history is negative for biopsy-confirmed malignancy within 5 years of randomization, with the exception of adequately treated basal cell or squamous cell carcinoma in situ.
• Patient is scheduled to receive kidney transplant from a deceased donor meeting the following criteria:
• Part A:
• receipt of an extended criteria donor (ECD) kidney, or
• receipt of a kidney donated after cardiac death (DCD), or
• receipt of a standard criteria donor (SCD) with cold ischemia time (CIT) ≥ 24 hours.
• Part B:
• receipt of an ECD kidney that has been preserved by cold storage (ECD/CS) for the entire period of cold ischemia time (CIT), regardless of duration
• receipt of an ECD kidney that has been preserved by machine perfusion (ECD/MP) for any interval of time during the period of cold ischemia, where total CIT has been at least 26 hours
• receipt of an SCD kidney that has been preserved by cold storage (SCD/CS) where total CIT has been at least 26 hours
• receipt of an SCD kidney that has been preserved by machine perfusion (SCD/MP) for any interval of time during the period of cold ischemia, where total CIT has been at least 26 hours.
• Patient is dialysis dependent at the time of transplant as documented by: a) the requirement for at least 2 dialysis sessions/week during the 56 days prior to transplant, or b) the planned removal of any remaining native kidney at the time of transplant, or c) the opinion of the investigator that the patient has no remaining native renal function (Part A only), or d) the investigator has provided documentation to the Medical Monitor that the patient has no remaining native renal function (e.g., documentation that the patient is anuric, with urine output <50 mL/day) (Part B only).

You may not qualify if…

• Patient has participated in an investigational drug study in the last 30 days.
• Patient has known allergy or has participated in prior study with siRNA.
• Patient is HCV-positive
• Patient is HIV-positive
• Patient is scheduled to undergo multiorgan transplantation.
• Patient has a planned transplant of kidneys that are implanted en bloc (dual kidney transplant).
• Patient has planned transplant of kidneys from donors < 6 years of age.
• Patient has planned transplant of dual kidneys (from the same donor) transplanted not en bloc (as in the case of dual ECD donor kidneys).
• Patient is scheduled for transplantation of a kidney from a donor who is known to have received an investigational therapy (under another IND) for ischemic/reperfusion injury immediately prior to organ recovery.
• Patient is scheduled to receive a living donor kidney.
• Patient is scheduled to receive an ABO-incompatible donor kidney.
• Patient is scheduled to receive an organ from a donor that meets both DCD and ECD criteria.
• Patient is scheduled to receive an organ from a donor that meets DCD criteria (exclusion applicable to Part B only).
• Patient has history or presence of a medical condition or disease that in the investigator's assessment would place the patient at an unacceptable risk for study participation.

Where it is running

• University of Alabama Birmingham — Birmingham, Alabama, United States
• Loma Linda University Medical Center — Loma Linda, California, United States
• University of Southern California — Los Angeles, California, United States
• Cedars-Sinai Medical Center — Los Angeles, California, United States
• Transplant Research Institute (TRI; formerly NIT) — Los Angeles, California, United States
• UCLA Medical Center — Los Angeles, California, United States
• UC Davis Medical Center — Sacramento, California, United States
• California Pacific Medical Center — San Francisco, California, United States
• UCSF Medical Center — San Francisco, California, United States
• University of Colorado Health Science Center — Aurora, Colorado, United States
• Washington Hospital Center — Washington D.C., District of Columbia, United States
• University of Florida — Gainesville, Florida, United States
• University of Miami — Miami, Florida, United States
• Lifelink Healthcare Institute — Tampa, Florida, United States
• Piedmont Hospital — Atlanta, Georgia, United States
• Emory University — Atlanta, Georgia, United States
• Rush University — Chicago, Illinois, United States
• University of Illinois Chicago — Chicago, Illinois, United States
• University of Maryland — Baltimore, Maryland, United States
• Johns Hopkins University — Baltimore, Maryland, United States
• University of Michigan — Ann Arbor, Michigan, United States
• Mayo Clinic Rochester — Rochester, Minnesota, United States
• Saint Barnabas Medical Center — Livingston, New Jersey, United States
• Columbia University — New York, New York, United States
• Cornell University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.